Mylan
Search results
NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc.
- Pfizer Completes Transaction to Combine Its
Viatris common stock, in each case on a fully diluted,...
- Pfizer Announces Details for When-Issued and Ex-Distribution ...
During this time, a Pfizer stockholder will have the option...
- Mylan and Pfizer Announce Viatris as the New Company Name in ...
HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (NASDAQ:...
- Pfizer Completes Transaction to Combine Its
During this time, a Pfizer stockholder will have the option of selling the right to receive shares of Viatris common stock in the spin-off while retaining shares of Pfizer common stock. This option will be available under the temporary Nasdaq symbol “VTRSV”.
Nov 12, 2019 · HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘viǝ-trīs).
Nov 16, 2020 · (RTTNews) - Pfizer Inc. (PFE) has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. The combined company was renamed Viatris in connection with the closing....
- Rttnews
Nov 18, 2020 · November 18, 2020 – Pfizer Inc (NYSE: PFE) has completed its previously announced spin-off of Viatris Inc. (NYSE: VTRS). Under the terms of the agreement, Pfizer shareholders will receive 0.124079 shares of Viatris common stock for every Pfizer share that is held at the close of business on November 13, 2020.
Nov 16, 2020 · Pfizer Inc. announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc.. In the distribution, Pfizer...
Nov 2, 2020 · Pfizer and Mylan unveiled their deal last July and drew the curtain on the Viatris name 12 months ago. The deal allows Pfizer a greater focus on the innovative drug franchise after its...
